Silk Road Medical - SILK Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month target prices for Silk Road Medical's stock. Their SILK share price forecasts range from $38.00 to $70.00. On average, they predict the company's share price to reach $50.83 in the next twelve months. This suggests that the stock has a possible downside of 6.3%.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $52.85 at the beginning of the year. Since then, SILK stock has increased by 2.6% and is now trading at $54.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SILK earnings forecast.

Silk Road Medical, Inc (NASDAQ:SILK) posted its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.15. The firm earned $37.37 million during the quarter, compared to analyst estimates of $33.84 million. Silk Road Medical had a negative net margin of 45.16% and a negative trailing twelve-month return on equity of 86.73%.

Silk Road Medical updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $134.00 million-$137.00 million, compared to the consensus revenue estimate of $130.60 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.91%), Peregrine Capital Management LLC (0.70%), Calamos Advisors LLC (0.06%) and Bank Julius Baer & Co. Ltd Zurich (0.05%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and Tony M Chou.
View institutional ownership trends.

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $54.25.

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $2.07 billion and generates $101.47 million in revenue each year. The company earns $-49,810,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

The company employs 352 workers across the globe.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for the company is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at investors@silkroadmed.com, or via fax at 408-720-9013.